"The U.S. Department of Health and Human Services today launched an annual challenge designed to identify and honor clinicians and health care teams that have helped their patients control high blood pressure and prevent heart attacks and strokes."...
For the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension.
DOSAGE AND ADMINISTRATION
Therapy is usually started with one 2.5 mg tablet of INVERSINE (mecamylamine) twice a day. This initial dosage should be modified by increments of one 2.5 mg tablet at intervals of not less than 2 days until the desired blood pressure response occurs (the criterion being a dosage just under that which causes signs of mild postural hypotension).
The average total daily dosage of INVERSINE (mecamylamine) is 25 mg, usually in three divided doses. However, as little as 2.5 mg daily may be sufficient to control hypertension in some patients. A range of two to four or even more doses may be required in severe cases when smooth control is difficult to obtain. In severe or urgent cases, larger increments at smaller intervals may be needed. Partial tolerance may develop in certain patients, requiring an increase in the daily dosage of INVERSINE (mecamylamine) .
Administration of INVERSINE (mecamylamine) after meals may cause a more gradual absorption and smoother control of excessively high blood pressure. The timing of doses in relation to meals should be consistent. Since the blood pressure response to antihypertensive drugs is increased in the early morning, the larger dose should be given at noontime and perhaps in the evening. The morning dose, as a rule, should be relatively small and in some instances may even be omitted.
The initial regulation of dosage should be determined by blood pressure readings in the erect position at the time of maximal effect of the drug, as well as by other signs and symptoms of orthostatic hypotension.
The effective maintenance dosage should be regulated by blood pressure readings in the erect position and by limitation of dosage to that which causes slight faintness or dizziness in this position. If the patient or a relative can use a sphygmomanometer, instructions may be given to reduce or omit a dose if readings fall below a designated level or if faintness or lightheadedness occurs. However, no change should be instituted without the knowledge of the physician.
Close supervision and education of the patient, as well as critical adjustment of dosage, are essential to successful therapy.
Other Antihypertensive Agents
When INVERSINE (mecamylamine) is given with other antihypertensive drugs, the dosage of these other agents, as well as that of INVERSINE (mecamylamine) , should be reduced to avoid excessive hypotension. However, thiazides should be continued in their usual dosage, while that of INVERSINE (mecamylamine) is decreased by at least 50 percent.
Tablets INVERSINE (mecamylamine) , 2.5 mg, are slightly yellow, round compressed tablets, coded LBS01. They are supplied as follows:
NDC 17205-0626-1 in bottles of 100.
Store at 25°C (77°F); excursions permitted to 15-30°(59-86°F)
(see USP Controlled Room (Temperature)
Manufactured by: Siegfried CMS Ltd., Zofingen, Switzerland for Targacept, Inc., Wmston-Salem, NC 27101. FDA revision date: 10/18/2002
Last reviewed on RxList: 12/2/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Inversine Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on handling your hypertension.